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Even in the presence of an adequate oxygen supply, many tumors metabolize the majority of the glucose they take up through 
glycolysis. It has been a long-held belief that this glycolytic phenotype is due to cancer-specific defects in mitochondrial oxi-
dative phosphorylation. In this issue of Cancer Cell, Fantin et al. now report that most tumor cells have a substantial reserve 
capacity to produce ATP by oxidative phosphorylation when glycolysis is suppressed. These new data add to mounting evi-
dence that the high rate of glycolysis exhibited by most tumors is required to support cell growth rather than to compensate 
for defect(s) in mitochondrial function.Before the introduction of free oxygen into 
the atmosphere, life on earth depended on 
glycolysis for energy production. With the 
rise of atmospheric oxygen, cells evolved 
the ability to use oxidative phosphoryla-
tion (OXPHOS) to produce more energy 
per metabolite than the more ancient 
anaerobic pathway. Most present day cells 
have developed the ability to differentially 
utilize these two ATP-generating path-
ways depending on physiologic circum-
stances. Pasteur was the first to observe 
the reciprocal relationship between these 
processes when he found that glycolysis 
was inhibited in the presence of oxygen 
(Pasteur, 1861). In contrast, Warburg 
observed that some tumors preferentially 
utilized glycolysis instead of OXPHOS in 
the presence of oxygen (Warburg, 1930). 
Since Warburg’s pioneering studies, 
aerobic glycolysis has been observed in 
a wide variety of cancers. The high rate 
of glucose utilization by such tumors can 
be visualized clinically by positron emis-
sion tomography (PET) imaging of tumor 
uptake of 18F-2-deoxyglucose. Given the 
inefficiency of glycolysis in producing ATP, 
the high rate of glycolysis by tumor cells 
has long puzzled cancer biologists. In this cancer cell June 2006 issue of Cancer Cell, Fantin et al. provide 
new insight into this problem by examin-
ing the effects of lactate dehydrogenase 
A (LDH-A) suppression on cancer cell 
metabolism, growth, and tumorigenicity 
(Fantin et al., 2006).
The enzyme LDH mediates a redox 
reaction at the end of glycolysis in which 
pyruvate is reduced to lactate when the 
cytosolic NADH/NAD+ ratio is high. This 
reaction permits the regeneration of 
NAD+, needed as an electron acceptor 
to maintain cytosolic glucose catabolism. 
To sustain glycolysis when LDH-A is sup-
pressed, the cells must compensate by 
oxidizing glycolytic NADH through the 
electron transport chain. Fantin et al. 
found that LDH-A inhibition in neu-initi-
ated mammary epithelial tumor cell lines 
resulted in enhanced OXPHOS. The data 
demonstrate that the glycolytic shift in 
these tumor cells is not due to a defect in 
the ability to carry out oxidative phospho-
rylation. In fact, the efficiency with which 
the tumor cell mitochondria produced ATP 
through electron transport chain activity 
was identical to the ATP production effi-
ciency of mitochondria from nontrans-
formed epithelial cells.Although there was a compensa-
tory increase in mitochondrial respira-
tion, Fantin et al. observed that inhibition 
of LDH-A suppressed the proliferative 
and tumorigenic potential of cancer cells. 
There are several potential explanations 
for these observations that are in keeping 
with the hypothesis that a high rate of gly-
colysis is advantageous to growing cells. 
First, although OXPHOS produces more 
energy per molecule of glucose than gly-
colysis, glycolysis is capable of producing 
ATP considerably faster than OXPHOS as 
long as glucose supplies are unlimited. 
Growing cells have an enormous demand 
for ATP to fuel their growth, and glycoly-
sis is much better suited to meeting this 
demand (Pfeiffer et al., 2001). In contrast, 
the rate at which ATP can be generated 
from glucose by oxidative metabolism is 
limited by the slow rate of NADH shuttling 
from the cytosol to the mitochondrial elec-
tron transport chain (Figure 1). Consistent 
with this, when LDH-A was suppressed, the 
compensatory increase in oxidative phos-
phorylation was unable to keep up with the 
cancer cell’s metabolic demands, and both 
the mitochondrial membrane potential and 
ATP levels of the cell declined.Figure 1. Cancer cells exhibit constitutive 
aerobic glycolysis
In nontransformed cells, glucose uptake is 
regulated by receptor activation of PI3K. 
Activating mutations in PI3K or Akt lead to 
glucose uptake in excess of the cell’s require-
ments, resulting in excess production of pyru-
vate and nADH through glycolysis. In cancer 
cells, some of the pyruvate produced in 
excess of that needed to maintain the mito-
chondrial membrane potential is shunted 
into lipid synthesis through a truncated TCA 
cycle. The remaining pyruvate is converted to 
lactate by LDH-A, regenerating nAD+ need-
ed to maintain glycolysis. When glycolysis is 
suppressed by LDH-A shRnA, cancer cells 
compensate with increased oxidative phos-
phorylation. The slower rate through which 
oxidative phosphorylation generates ATP 
does not appear to be able to keep up with 
a cancer cell’s bioenergetic needs, leading 
to a decrease in mitochondrial membrane 
potential, cessation of cell growth, and inhibi-
tion of tumorigenesis.419
	 p r e v i e w sA second potential reason for why 
suppression of glycolysis results in 
decreased cell growth and tumorigenic-
ity is that glucose derivatives contribute 
to more than ATP generation during cell 
growth. Glycolytic metabolites have been 
shown to be required for both fatty acid 
production and the maintenance of non-
essential amino acid pools during growth. 
The generation of NADPH, a cofactor for 
many synthetic reactions, is produced in 
growing cells by oxidative degradation of 
glucose by glucose-6-phosphate dehy-
drogenase (G6PD). The resulting ribose 
is disposed of by returning the carbon to 
the glycolytic pathway using the transal-
dolase/transketolase complex.
The increase in OXPHOS upon LDH-
A suppression demonstrates that the 
tumor cells preferentially maintain their 
metabolism through glycolysis despite a 
considerable residual capacity to engage 
in OXPHOS. What can account for this 
preference in the absence of a defect in 
oxidative phosphorylation? It has been 
suggested that the preferential use of gly-
colysis by tumor cells provides the cells 
with a competitive advantage under con-
ditions of hypoxia (Gatenby and Gillies, 
2004). Consistent with this proposal, cells 
with attenuated levels of LDH-A were found 
to have a reduced ability to grow under 
conditions of hypoxia. In tumors exposed 
to hypoxia, the transcription factor HIF-1α 
is activated and induces the transcription of 
glycolytic enzymes (Dang and Semenza, 
1999). Fantin et al. propose that the high 
rate of tumor glycolysis results from onco-
gene-directed signaling pathways that 
upregulate HIF-1α such as those initiated 
by Ras, Src, and Her-2/Neu. In addition 
to increasing the expression of glyco-
lytic genes, HIF-1α transcription leads to 
repression of pyruvate utilization by mito-
chondria. Recently, two groups have shown 
that HIF-1α also induces the expression of 
pyruvate dehydrogenase kinase 1 (PDK1) 
(Kim et al., 2006; Papandreou et al., 2006). 
When expressed, PDK1 phosphorylates 
and inactivates mitochondrial pyruvate 
dehydrogenase (PDH). This suppression 
of substrate entry into the citric acid cycle 
would further enhance the dependence of 
cells on glycolysis for ATP production.
At first blush, oncogene induction 
of HIF-1α appears to explain both the 
enhanced rate of glycolysis and the 
repressed state of oxidative phosphoryla-
tion observed in tumors. However, there 
are two recent observations that challenge 
this simple interpretation. First, constitutive 420 activation of HIF-1α, while inducing glyco-
lysis, appears to suppress tumor growth 
(Mack et al., 2003). Second, the ability of 
tumors to produce sufficient quantities of 
cytosolic acetyl-CoA to fuel the synthesis 
of lipids needed for membrane synthesis 
and isoprenoids for lipid modification of 
signaling proteins depends on continued 
pyruvate degradation by mitochondrial 
PDH. The resulting mitochondrial acetyl-
CoA is combined with oxaloacetate to form 
citrate. When mitochondrial respiration is 
low, the citrate moves down its concentra-
tion gradient into the cytosol by means of 
the tricarboxylic acid transporter. In the 
cytosol, the enzyme ATP-citrate lyase 
(ACL) converts citrate into acetyl-CoA and 
oxaloacetate. The oxaloacetate is returned 
to the mitochondria to complete a truncated 
citric acid cycle, and the remaining acetyl-
CoA provides a glucose-derived substrate 
for cytosolic fatty acid synthesis (Bauer et 
al., 2005). This glucose-dependent produc-
tion of cytosolic acetyl-CoA contributes to 
the ability of glycolysis to fuel tumor growth, 
as ACL inhibition in cancer cells results in 
the suppression of fatty acid synthesis and 
tumor growth (Hatzivassiliou et al., 2005). 
The ability of glucose to fuel lipid synthesis 
in this manner would be inhibited by HIF-
1α induction of PDK1.
What then explains the high rate of 
glycolysis observed in tumors? Recently, 
Elstrom et al. (2004) have proposed that 
the high rate of glycolysis is driven by 
oncogene-directed increases in glucose 
uptake and metabolism. Oncogenic acti-
vation of the PI3K/Akt/Tor pathway results 
in coordinated upregulation of glucose 
transporters, enhanced glucose capture 
through glucose phosphorylation by hex-
okinase, and commitment of glucose to 
degradation by activation of PFK-1 and/
or G6PD. In this model, oncogenic sign-
aling drives glucose uptake and metabo-
lism in excess of cellular needs. Because 
most tumor cells cannot store carbon as 
glycogen or triglyceride, the excess car-
bon from glycolysis must be secreted as 
lactate, and this requires LDH-A activity. 
As Fantin et al. found, interrupting this 
mechanism of disposal increases pyru-
vate metabolism through mitochondrial 
oxidation, but LDH-A attenuation also 
arrested cell proliferation. This effect on 
cell proliferation is unexpected and raises 
further interesting questions about the 
connections between glucose metabolism 
and cancer cell physiology. For example, 
what is the mechanism of the effect on 
proliferation? Is this due to interference with biosynthesis, to signaling effects of 
accumulated metabolic intermediates like 
pyruvate, or to other mechanisms?
In summary, the paper by Fantin et al. 
(2006) adds to the growing evidence that 
aerobic glycolysis contributes to cancer 
cell growth and tumorigenicity. Warburg’s 
original hypothesis that aerobic glycoly-
sis results from tumor-specific mutations 
in oxidative phosphorylation no longer 
seems tenable. Nevertheless, these new 
insights raise as many questions as they 
answer. The time has come for cancer 
biologists to dust off their biochemistry 
textbooks. It seems there are a few chap-
ters that still need to be written.
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